BioXcel Therapeutics (BTAI) Key Ratios

Stock Card

$0.08

$-0.04 (-34.55%)

As on 04-Sep-2026 13:40EDT

Market cap

$6 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

P/B Ratio

27.5

Div. Yield

0 %

Key Ratios and Highlights

Growth Score (%)	Quarterly		Annual (TTM)
Particulars	QoQ	YoY	1-Year	3-Years	5-Years
Revenue	-11.65	51.67	-14.52	-10.59	95.86
EBIT	-23.11	30.13	-53.63	19.78	7.90
Net Profit	-15.93	23.32	-39.08	18.32	5.23
EPS	-15.93	50.74	56.99	24.63	13.90
Book Value	--	--	--	--	--

Key Ratios (%)	Average		Annual (TTM)
Particulars	3-Years	5-Years	TTM	Dec-25	Dec-24
EBIT-Margin	-7,404.82	-16,056.55	-7,228.57	-8,241.90	-1,962.49
Net Margin	--	-124,517.73	-9,549.87	--	--
Return on equity	-537.71	-354.80	--	74.14	79.67
Return on Capital	-321.74	-219.76	--	-581.46	-217.82
Return on Assets	-134.13	-104.65	-121.48	-167.91	-106.39
Debt to Equity (x)	--	--	0.00	-1.15	-1.11

Profitability

View Detailed Peer Comparison

ROCE

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	--	-581.46	-217.82	-165.94	-84.14	-49.43
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

ROE

Profit after tax / Average Net worth * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	--	74.14	79.67	-1,766.94	-111.08	-49.78
Peer Median	-40.40	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

ROA

-121.48

Lower than Peers by 90.50

Profit after tax / Average Total assets * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	-121.48	-167.91	-106.39	-128.10	-74.45	-46.42
Peer Median	-30.98	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EBIT Margin

-7,228.57

Lower than Peers by 7,144.95

Operating profit (EBIT) / Net Sales * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	-7,228.57	-8,241.90	-1,962.49	-12,010.07	-42,011.73	--
Peer Median	-83.62	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Net Margin

-9,549.87

Lower than Peers by 9,457.20

Net profit / Total Income (Net sales plus other income) * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	-9,549.87	-10,887.38	-2,630.14	-12,974.86	-6,694.55	-242,340.91
Peer Median	-92.67	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Cash Profit Margin

-0.05

Lower than Peers by 0.05

(Net profit + Depreciation) / Gross Sales * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	-0.05	--	--	--	--	--
Peer Median	0.00	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

-14.52

Lower than Peers by 68.47

Year on year growth in net sales

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	-14.52	-0.72	0.64	2.68	--	-1.00
Peer Median	53.95	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EBIT Growth

-53.63

Lower than Peers by 52.83

Year on year growth in operating profit (EBIT)

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	-53.63	-18.99	73.17	-5.20	-47.33	-29.94
Peer Median	-0.80	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Net Profit Growth

-39.08

Lower than Peers by 31.78

Year on year growth in profit after tax

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	-39.08	-17.28	66.71	-8.02	-55.45	-30.02
Peer Median	-7.30	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EPS Growth

56.99

Higher than Peers by 42.34

Year on year growth in earnings per share

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	56.99	0.71	0.80	-15.47	0.90	-0.13
Peer Median	14.65	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Book Value Growth

31.11

Higher than Peers by 41.28

Year on year growth in book value per share

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	31.11	--	--	--	--	--
Peer Median	-10.18	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

Total debt / Net worth

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	--	-1.15	-1.11	-1.79	1.23	0.01
Peer Median	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Short term debt to equity ratio

-0.90

(Short term borrowings / Net worth)

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	-0.90	-0.26	0.00	-0.01	0.00	0.00
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Current Ratio

0.21

Lower than Peers by 5.60

Current Assets / Current Liabilities and Provisions

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	0.21	0.83	1.68	2.65	6.17	14.21
Peer Median	5.81	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Quick Ratio

0.21

Lower than Peers by 5.49

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	0.21	0.82	1.65	2.57	6.11	14.21
Peer Median	5.70	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Interest Coverage

-3.11

Lower than Peers by 1.03

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	-3.11	-3.12	-2.94	-12.45	-19.18	-2,673.38
Peer Median	-2.09	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

11.05

Lower than Peers by 8.09

Debtors outstanding / Net Sales * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	11.05	36.29	5.78	5.14	66.13	--
Peer Median	19.14	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Asset Turnover

0.01

Lower than Peers by 0.05

Sales / Average Total Assets

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	0.01	0.02	0.04	0.01	0.00	--
Peer Median	0.06	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Receivable days

Average Debtors / Sales * 365

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	--	103.54	16.28	42.22	120.78	--
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Inventory Days

Average Inventory / Sales * 365

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	--	1,560.11	227.54	576.28	18,125.53	--
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Payable days

Average Creditors / Cost of goods sold * 365

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	--	34,176.49	2,526.24	3,461.47	136,110.41	5,323.18
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Cash Conversion Cycle

Receivable Days + Inventory Days - Payable Days

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	--	-32,512.84	-2,282.43	-2,842.97	-117,864.11	--
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

Current share price divided by earning per share in the last twelve months

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	--	-0.28	-0.02	-0.03	-3.64	-0.33
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Price / Book Value

27.50

Higher than Peers by 22.32

Current share price divided by book value per share in the latest financial year

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	27.50	-0.20	-0.01	-0.10	7.85	0.16
Peer Median	5.18	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Dividend Yield

Dividend per share in the past twelve months divided by current share price

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	--	--	--	--	--	--
Peer Median	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EV/EBITDA

-0.75

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	-0.75	-1.92	-1.68	-0.25	-3.20	1.84
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Market Cap

Lower than Peers by 140

Current Share price multiplied by latest total number of shares outstanding

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
BioXcel Therapeutics (BTAI)	6	--	--	--	--	--
Peer Median	146	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly